bifeprunox is a compound (a D2 and 5-HT1A partial agonist), being studied for the treatment of psychosis and mood disorders, such as schizophrenia. The New Drug Application (NDA) for bifeprunox was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of schizophrenia and maintenance of stability, and has been officially filed by the FDA.

Schizophrenia is a chronic and complex mental illness typically characterized by delusions, hallucinations, illogical and disorganized thinking and social withdrawal, which can severely interfere with daily life. Many people with schizophrenia have difficulty distinguishing between real and unreal experiences. Research suggests several factors contribute to schizophrenia including genetics, environmental factors and chemical imbalances. While there is no cure for schizophrenia, many people who suffer with this mental illness can manage their symptoms with proper treatment. A combination of antipsychotic medication, psychosocial support and rehabilitation programs is usually recommended for management of the disease.

Leave a comment

Your email address will not be published. Required fields are marked *